株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

サラセミア:パイプライン製品の分析

Thalassemia - Pipeline Review, H2 2016

発行 Global Markets Direct 商品コード 245974
出版日 ページ情報 英文 144 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.81円で換算しております。
Back to Top
サラセミア:パイプライン製品の分析 Thalassemia - Pipeline Review, H2 2016
出版日: 2016年08月31日 ページ情報: 英文 144 Pages
概要

サラセミアは、ヘモグロビンおよび赤血球の産生に影響を及ぼす遺伝的な血液の疾病であり、ぐずつき、顔色不良、頻繁な感染、発育障害、食欲不振および黄疸などが症状として挙げられます。発病要因は遺伝的であり、治療には輸血および骨髄移植などが行われます。

当レポートでは、サラセミアに対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

イントロダクション

  • 調査範囲

サラセミアの概要

治療薬の開発

  • パイプライン製品の概要
  • パイプライン製品の比較分析

サラセミア:企業で開発中の治療薬

サラセミア:大学/機関で研究中の治療薬

サラセミア:パイプライン製品の概況

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品

サラセミア:企業で開発中の製品

サラセミア:大学/機関で研究中の製品

サラセミアの治療薬開発に従事している企業

  • Acceleron Pharma, Inc.
  • Acetylon Pharmaceuticals, Inc.
  • Acino Pharma AG
  • Agios Pharmaceuticals, Inc.
  • Alnylam Pharmaceuticals, Inc.
  • Bellicum Pharmaceuticals, Inc.
  • Bluebird bio, Inc.
  • Editas Medicine, Inc.
  • Emmaus Medical, Inc.
  • Errant Gene Therapeutics, LLC
  • Gamida Cell Ltd.
  • Incyte Corporation
  • Ionis Pharmaceuticals, Inc.
  • IRBM Science Park SpA
  • Johnson & Johnson
  • Kiadis Pharma B.V.
  • La Jolla Pharmaceutical Company
  • Merck & Co., Inc.
  • PharmaEssentia Corporation
  • Protagonist Therapeutics Inc.
  • Sangamo BioSciences, Inc.

サラセミア:治療薬の評価

  • 単剤製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

サラセミア:最近のパイプライン動向

サラセミア:休止中のプロジェクト

サラセミア:製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8416IDB

Summary

Global Markets Direct's, 'Thalassemia - Pipeline Review, H2 2016', provides an overview of the Thalassemia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Thalassemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Thalassemia and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Thalassemia
  • The report reviews pipeline therapeutics for Thalassemia by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Thalassemia therapeutics and enlists all their major and minor projects
  • The report assesses Thalassemia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Thalassemia

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Thalassemia
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Thalassemia pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Thalassemia Overview
  • Therapeutics Development
    • Pipeline Products for Thalassemia - Overview
    • Pipeline Products for Thalassemia - Comparative Analysis
  • Thalassemia - Therapeutics under Development by Companies
  • Thalassemia - Therapeutics under Investigation by Universities/Institutes
  • Thalassemia - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Thalassemia - Products under Development by Companies
  • Thalassemia - Products under Investigation by Universities/Institutes
  • Thalassemia - Companies Involved in Therapeutics Development
    • Acceleron Pharma, Inc.
    • Acetylon Pharmaceuticals, Inc.
    • Acino International AG
    • Agios Pharmaceuticals, Inc.
    • Alnylam Pharmaceuticals, Inc.
    • Bellicum Pharmaceuticals, Inc.
    • Bluebird bio, Inc.
    • Editas Medicine, Inc.
    • Emmaus Medical, Inc.
    • Errant Gene Therapeutics, LLC
    • Gamida Cell Ltd.
    • Gilead Sciences, Inc.
    • Incyte Corporation
    • Ionis Pharmaceuticals, Inc.
    • IRBM Science Park SpA
    • Johnson & Johnson
    • Kiadis Pharma N.V.
    • La Jolla Pharmaceutical Company
    • Merck & Co., Inc.
    • Pfizer Inc.
    • PharmaEssentia Corporation
    • Sangamo BioSciences, Inc.
  • Thalassemia - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • ACY-957 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AG-348 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ALN-TMP - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ambrisentan - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Antisense Oligonucleotides to Inhibit BCL11A and KLF1 for Hematological Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ATIR-201 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BB-305 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • benserazide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BPX-501 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BtX-13 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CNTO-530 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CordIn - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Drug for Thalassemia and Hemochromatosis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene Therapy for Sickle Cell Disease and Thalassemia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • glutamine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GSK-2696277 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IONISTMPRSS-6LRx - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LJPC-401 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • luspatercept - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • M-009 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • M-012 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NiCord - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PF-04447943 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Piggybac-HBB - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PTG-300 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RNAi Gene Therapy for Sickle Cell Disease and Beta Thalassemia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ruxolitinib phosphate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SCD-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • sirolimus - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule for Beta Thalassemia and Sickle Cell Anemia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit Histone Deacetylase 1 for Beta-Thalassemia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit PRMT5 for Haemoglobinopathies and Solid Tumours - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • sotatercept - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Stem Cell Therapy for Beta Thalassemia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Stem Cell Therapy for Beta Thalassemia and Sickle Cell Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Thalagen - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Thalassemia - Dormant Projects
  • Thalassemia - Product Development Milestones
    • Featured News & Press Releases
      • Jul 28, 2016: Protagonist Therapeutics Receives SBIR Funding for the Development of Injectable Hepcidin Mimetics for Treatment of Iron Overload Disorders
      • Jun 10, 2016: Acceleron and Celgene Announce Updated Results from an Ongoing Phase 2 Study of Luspatercept in Beta-Thalassemia Presented at the 21st Congress of the European Hematology Association
      • May 19, 2016: Agios to Present Clinical data from PKR Activator AG-348 at the 21st Congress of the European Hematology Association
      • May 19, 2016: Acceleron Announces Data Presentations with Luspatercept at the 21st Congress of the European Hematology Association
      • May 09, 2016: Merganser Biotech Announces Issuance of U.S. Patent 9,315,545 Covering Development Compound M012
      • May 06, 2016: Drug-like Compound Shows Promise in Treating Two Blood Diseases
      • May 04, 2016: Acetylon Pharmaceuticals Publishes New Mechanism for the Treatment of Sickle Cell Disease/Beta-Thalassemia with Selective HDAC1/2 Inhibition in PLoS One
      • Feb 24, 2016: Merganser Biotech Initiates First Clinical Trial
      • Dec 07, 2015: Acetylon Presents Data on the Pharmacokinetics and HbE/HbG Hemoglobin Induction Following Once Daily Dosing of an Oral HDAC1,2 Inhibitor in Animal Models
      • Dec 02, 2015: Emmaus Life Sciences to Present Additional New Data from its Phase 3 Sickle Cell Disease Trial at 57th Annual ASH Meeting
      • Nov 05, 2015: Acceleron Announces New Data on Luspatercept at the 2015 American Society of Hematology Annual Meeting
      • Oct 23, 2015: Acceleron Highlights Phase 3 Studies, New Clinical Results and Research Strategies at Research and Development Day Event
      • Oct 19, 2015: La Jolla Pharmaceutical Doses First Patient in Phase 1 Clinical Trial of LJPC-401 in Patients at Risk of Iron Overload
      • Aug 11, 2015: La Jolla Pharmaceutical Company Announces FDA Acceptance of IND for LJPC-401
      • Jun 12, 2015: Acceleron Announces New Luspatercept Phase 2 Clinical Results at the 20th Congress of the European Hematology Association
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Thalassemia, H2 2016
  • Number of Products under Development for Thalassemia - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Thalassemia - Pipeline by Acceleron Pharma, Inc., H2 2016
  • Thalassemia - Pipeline by Acetylon Pharmaceuticals, Inc., H2 2016
  • Thalassemia - Pipeline by Acino International AG, H2 2016
  • Thalassemia - Pipeline by Agios Pharmaceuticals, Inc., H2 2016
  • Thalassemia - Pipeline by Alnylam Pharmaceuticals, Inc., H2 2016
  • Thalassemia - Pipeline by Bellicum Pharmaceuticals, Inc., H2 2016
  • Thalassemia - Pipeline by bluebird bio, Inc., H2 2016
  • Thalassemia - Pipeline by Editas Medicine, Inc., H2 2016
  • Thalassemia - Pipeline by Emmaus Medical, Inc., H2 2016
  • Thalassemia - Pipeline by Errant Gene Therapeutics, LLC, H2 2016
  • Thalassemia - Pipeline by Gamida Cell Ltd., H2 2016
  • Thalassemia - Pipeline by Gilead Sciences, Inc., H2 2016
  • Thalassemia - Pipeline by Incyte Corporation, H2 2016
  • Thalassemia - Pipeline by Ionis Pharmaceuticals, Inc., H2 2016
  • Thalassemia - Pipeline by IRBM Science Park SpA, H2 2016
  • Thalassemia - Pipeline by Johnson & Johnson, H2 2016
  • Thalassemia - Pipeline by Kiadis Pharma N.V., H2 2016
  • Thalassemia - Pipeline by La Jolla Pharmaceutical Company, H2 2016
  • Thalassemia - Pipeline by Merck & Co., Inc., H2 2016
  • Thalassemia - Pipeline by Pfizer Inc., H2 2016
  • Thalassemia - Pipeline by PharmaEssentia Corporation, H2 2016
  • Thalassemia - Pipeline by Sangamo BioSciences, Inc., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Thalassemia - Dormant Projects, H2 2016

List of Figures

  • Number of Products under Development for Thalassemia, H2 2016
  • Number of Products under Development for Thalassemia - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Top 10 Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top